This second trial of COMP360 (psilocybin) by COMPASS will investigate the effectiveness of the psychedelic for anorexia in 60 patients.
The trial is the 9th psychedelic trial for eating disorders and currently the largest.
Trial DetailsThis study aims to explore the efficacy and safety of COMP360 25 mg as compared to COMP360 1 mg (control condition) administered with psychological support in participants with Anorexia Nervosa
NCT Number NCT05481736
Sponsors & CollaboratorsCOMPASS Pathways
COMPASS Pathways is a publicly listed company (NASDAQ) that aims to develop psilocybin for treatment-resistant depression (TRD) for which it has completed a successful Phase IIb trial. It has gone public and has received substantial investment from atai.